AU2012298813B2 - Inhibitors of Nedd8-activating enzyme - Google Patents

Inhibitors of Nedd8-activating enzyme Download PDF

Info

Publication number
AU2012298813B2
AU2012298813B2 AU2012298813A AU2012298813A AU2012298813B2 AU 2012298813 B2 AU2012298813 B2 AU 2012298813B2 AU 2012298813 A AU2012298813 A AU 2012298813A AU 2012298813 A AU2012298813 A AU 2012298813A AU 2012298813 B2 AU2012298813 B2 AU 2012298813B2
Authority
AU
Australia
Prior art keywords
chemical entity
cancer
chloro
oxy
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012298813A
Other languages
English (en)
Other versions
AU2012298813A1 (en
Inventor
Ashley Sue Mccarron
Todd B. Sells
Matthew Stirling
Stephen G. Stroud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2012298813A1 publication Critical patent/AU2012298813A1/en
Application granted granted Critical
Publication of AU2012298813B2 publication Critical patent/AU2012298813B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012298813A 2011-08-24 2012-08-23 Inhibitors of Nedd8-activating enzyme Ceased AU2012298813B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24
US61/526,830 2011-08-24
PCT/US2012/052007 WO2013028832A2 (en) 2011-08-24 2012-08-23 Inhibitors of nedd8-activating enzyme

Publications (2)

Publication Number Publication Date
AU2012298813A1 AU2012298813A1 (en) 2013-05-02
AU2012298813B2 true AU2012298813B2 (en) 2016-07-28

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012298813A Ceased AU2012298813B2 (en) 2011-08-24 2012-08-23 Inhibitors of Nedd8-activating enzyme

Country Status (29)

Country Link
US (3) US8809356B2 (enExample)
EP (2) EP2748168A4 (enExample)
JP (1) JP6038150B2 (enExample)
KR (1) KR20140054288A (enExample)
CN (1) CN103889988B (enExample)
AR (1) AR087672A1 (enExample)
AU (1) AU2012298813B2 (enExample)
BR (1) BR112014004239A2 (enExample)
CA (1) CA2846231C (enExample)
CL (1) CL2014000441A1 (enExample)
CO (1) CO6900148A2 (enExample)
CR (1) CR20140128A (enExample)
DO (1) DOP2014000037A (enExample)
EA (1) EA031067B1 (enExample)
EC (1) ECSP14013263A (enExample)
GE (1) GEP201606522B (enExample)
HK (1) HK1199252A1 (enExample)
IL (1) IL231069B (enExample)
MA (1) MA35439B1 (enExample)
MX (1) MX2014002015A (enExample)
MY (1) MY166889A (enExample)
PE (1) PE20141146A1 (enExample)
PH (1) PH12014500419A1 (enExample)
SG (2) SG11201400102WA (enExample)
TN (1) TN2014000080A1 (enExample)
TW (1) TWI577667B (enExample)
UA (1) UA114894C2 (enExample)
UY (1) UY34292A (enExample)
WO (1) WO2013028832A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
WO2015002994A2 (en) * 2013-07-02 2015-01-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
WO2017183927A1 (ko) * 2016-04-20 2017-10-26 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (en) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191293A1 (en) * 2006-02-02 2007-08-16 Millennium Pharmaceuticals, Inc. Inhibitors of E1 activating enzymes
WO2010132110A1 (en) * 2009-05-14 2010-11-18 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
WO1997005132A1 (en) 1995-07-28 1997-02-13 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
EP1597255A1 (en) 2002-11-13 2005-11-23 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ME02789B (me) * 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
PL2773360T3 (pl) * 2011-11-03 2018-09-28 Millennium Pharmaceuticals, Inc. Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191293A1 (en) * 2006-02-02 2007-08-16 Millennium Pharmaceuticals, Inc. Inhibitors of E1 activating enzymes
WO2010132110A1 (en) * 2009-05-14 2010-11-18 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Also Published As

Publication number Publication date
US20180290983A1 (en) 2018-10-11
US20130150388A1 (en) 2013-06-13
US9850214B2 (en) 2017-12-26
EP3323414A1 (en) 2018-05-23
CN103889988A (zh) 2014-06-25
EP2748168A4 (en) 2015-04-22
AU2012298813A1 (en) 2013-05-02
KR20140054288A (ko) 2014-05-08
TN2014000080A1 (en) 2015-07-01
WO2013028832A2 (en) 2013-02-28
AR087672A1 (es) 2014-04-09
JP6038150B2 (ja) 2016-12-07
GEP201606522B (en) 2016-08-10
CA2846231A1 (en) 2013-02-28
EA201400249A1 (ru) 2014-05-30
PH12014500419A1 (en) 2020-06-22
TWI577667B (zh) 2017-04-11
CR20140128A (es) 2014-05-15
BR112014004239A2 (pt) 2017-03-21
MX2014002015A (es) 2014-03-27
CN103889988B (zh) 2018-05-04
PE20141146A1 (es) 2014-09-21
SG11201400102WA (en) 2014-03-28
US20150011572A1 (en) 2015-01-08
CO6900148A2 (es) 2014-03-20
US8809356B2 (en) 2014-08-19
MY166889A (en) 2018-07-24
HK1199252A1 (en) 2015-06-26
CA2846231C (en) 2017-06-20
UA114894C2 (uk) 2017-08-28
IL231069B (en) 2018-02-28
IL231069A0 (en) 2014-03-31
ECSP14013263A (es) 2014-04-30
UY34292A (es) 2013-04-05
JP2014524476A (ja) 2014-09-22
MA35439B1 (fr) 2014-09-01
EA031067B1 (ru) 2018-11-30
CL2014000441A1 (es) 2014-09-26
SG10201601023UA (en) 2016-03-30
NZ622220A (en) 2016-04-29
TW201313689A (zh) 2013-04-01
DOP2014000037A (es) 2014-04-15
EP2748168A2 (en) 2014-07-02
WO2013028832A3 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
JP6038150B2 (ja) Nedd8活性化酵素阻害剤
JP6184423B2 (ja) カルボン酸化合物
US10202389B2 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
JP5008778B2 (ja) 新規5−フルオロウラシル誘導体
EP2483272A2 (en) Pi3k (delta) selective inhibitors
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
NZ622220B2 (en) Inhibitors of nedd8-activating enzyme
HK1238244A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
HK1168344B (en) Novel 5-fluorouracil derivative

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired